Table 1. Demographic, clinical, and laboratory features of healthy controls and patients with psoriatic arthritis.
| Variables | Healthy controls (n = 18) |
Psoriatic arthritis (n = 18) |
p Value |
|---|---|---|---|
| Sex (F:M) | 8:10 | 7:11 | – |
| Age (y) | 42.93 ± 10.16 | 43.81 ± 8.33 | 0.27 |
| Height (cm) | 170 ± 8.5 | 159 ± 4.9 | 0.08 |
| Body weight (kg) | 65.13 ± 12.5 | 63.07 ± 12.58 | 0.12 |
| BMI (kg/m2) | 22.45 ± 3.05 | 23.95 ± 5.63 | 0.23 |
| Disease duration (y) | – | 8.87 ± 5.85 | – |
| DAS28 | – | 4.08 ± 0.56 | – |
| DAPSA | – | 23.08 ± 8.76 | – |
| ESR (mm 1st h) | 16.68 ± 4.54 | 26.04 ± 10.36 | 0.03a |
| CRP (mg/dL) | 3.93 ± 1.10 | 12.76 ± 15.18 | 0.01a |
| Total cholesterol (mg/dL) | 187.2 ± 24.3 | 193.6 ± 32.4 | 0.26 |
| HDL cholesterol (mg/dL) | 53.9 ± 11.6 | 45.5 ± 10.7 | 0.03a |
| LDL cholesterol (mg/dL) | 114.2 ± 22.3 | 115.7 ± 26.5 | 0.48 |
| TG (mg/dL) | 99.1 ± 9.2 | 101.4 ± 13.4 | 0.43 |
| IL-1 (pg/mL) | 145 ± 8.3 | 150 ± 9.4 | 0.18 |
| IL-6 (pg/mL) | 6.5 ± 5.3 | 18.5 ± 6.8 | 0.03a |
| TNF-α (pg/mL) | 3.8 ± 1.8 | 6.4 ± 2.6 | 0.02a |
| ICAM-1 (ng/mL) | 120 ± 5.3 | 175 ± 6.8 | 0.01a |
| VCAM-1 (ng/mL) | 920 ± 2.6 | 940 ± 4.8 | 0.01a |
| FMD% | 9.3 ± 1.4 | 6.3 ± 0.95 | 0.01a |
| EPCs (%) | 0.041 ± 0.001 | 0.020 ± 0.001 | 0.01a |
| CIMT (cm) | 0.045 ± 0.10 | 0.062 ± 0.018 | 0.01a |
Abbreviations: BMI, body mass index; CIMT, carotid intima-media thickness; CRP, C-reactive protein; DAPSA, disease activity in psoriatic arthritis; DAS28, disease activity score of 28 joints; EPCs, endothelial progenitor cells; ESR, erythrocyte sedimentation rate; F, female; FMD, flow-mediated dilation; HDL, high-density lipoprotein; ICAM-1, intracellular adhesion molecule; IL-1, interleukin-1; IL-6, interleukin-6; LDL, low-density lipoprotein; M, male; TG, triglycerides; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule.
Note: Data are presented as mean ± SD.
a
p < 0.05 statistically significant.